Identifying Drugs to
Watch

Drugs to Watch™ showcases drugs recently launched or likely to enter the market this year that are forecast to become blockbusters within five years and/or to transform treatment paradigms (blockbuster is defined by the common $1 billion annual sales milestone).

To identify this year’s Drugs to Watch 2024 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and 11 integrated data sets that span the R&D and commercialization lifecycle.

Drug selection criteria:

1. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2023 were selected for analysis, including drugs launched for a new indication that could be particularly impactful on the industry; drugs launched prior to 2023 were excluded.
2. We then filtered the dataset for drugs that had total forecast sales of $1 billion or more in 2027.

Clarivate experts then manually evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

From there, we determined 13 Drugs to Watch in 2024.

arrow_forwardSee Drugs to Watch 2024